$286.31 Million in Sales Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter

Wall Street analysts predict that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will post sales of $286.31 million for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Ionis Pharmaceuticals’ earnings. The highest sales estimate is $332.40 million and the lowest is $230.30 million. Ionis Pharmaceuticals posted sales of $144.42 million in the same quarter last year, which suggests a positive year-over-year growth rate of 98.2%. The business is scheduled to report its next quarterly earnings results on Friday, May 3rd.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year sales of $760.52 million for the current financial year, with estimates ranging from $727.87 million to $822.00 million. For the next fiscal year, analysts forecast that the company will post sales of $912.73 million, with estimates ranging from $595.60 million to $1.74 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, February 27th. The company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $2.20. The firm had revenue of $192.00 million during the quarter, compared to the consensus estimate of $159.59 million. Ionis Pharmaceuticals had a return on equity of 41.89% and a net margin of 45.64%. The business’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.03) EPS.

Several research firms have recently commented on IONS. ValuEngine raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 15th. Piper Jaffray Companies set a $75.00 price objective on Ionis Pharmaceuticals and gave the company a “neutral” rating in a report on Friday, March 22nd. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Morgan Stanley set a $71.00 price objective on Ionis Pharmaceuticals and gave the company a “hold” rating in a report on Friday, March 1st. Finally, BMO Capital Markets increased their price objective on Ionis Pharmaceuticals from $70.00 to $82.00 and gave the company an “outperform” rating in a report on Thursday, February 28th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $66.33.

Shares of NASDAQ IONS traded down $1.86 during trading hours on Thursday, hitting $83.76. The company had a trading volume of 799,498 shares, compared to its average volume of 1,032,840. The company has a market cap of $11.85 billion, a PE ratio of 28.30 and a beta of 2.42. The company has a current ratio of 7.88, a quick ratio of 7.85 and a debt-to-equity ratio of 0.53. Ionis Pharmaceuticals has a 1-year low of $39.07 and a 1-year high of $86.58.

In related news, Chairman Stanley T. Crooke sold 77,000 shares of the stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $60.77, for a total value of $4,679,290.00. Following the sale, the chairman now owns 109,634 shares in the company, valued at approximately $6,662,458.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Patrick R. O’neil sold 19,600 shares of the stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $59.25, for a total value of $1,161,300.00. Following the completion of the sale, the senior vice president now owns 23,673 shares in the company, valued at approximately $1,402,625.25. The disclosure for this sale can be found here. In the last three months, insiders sold 339,205 shares of company stock valued at $24,034,607. 2.44% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Daiwa Securities Group Inc. raised its stake in Ionis Pharmaceuticals by 29.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock valued at $48,000 after acquiring an additional 200 shares during the period. Keybank National Association OH increased its position in Ionis Pharmaceuticals by 1.2% during the 4th quarter. Keybank National Association OH now owns 21,606 shares of the company’s stock worth $1,168,000 after buying an additional 250 shares during the period. Brown Advisory Securities LLC increased its position in Ionis Pharmaceuticals by 4.7% during the 4th quarter. Brown Advisory Securities LLC now owns 6,151 shares of the company’s stock worth $330,000 after buying an additional 276 shares during the period. Huntington National Bank increased its position in Ionis Pharmaceuticals by 159.3% during the 4th quarter. Huntington National Bank now owns 638 shares of the company’s stock worth $34,000 after buying an additional 392 shares during the period. Finally, ETF Managers Group LLC increased its position in Ionis Pharmaceuticals by 15.7% during the 4th quarter. ETF Managers Group LLC now owns 2,956 shares of the company’s stock worth $160,000 after buying an additional 402 shares during the period. Institutional investors and hedge funds own 85.05% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Recommended Story: Consumer Price Index (CPI)

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.